« Return to News | Awards & Advancement

Celerion gains membership in U.K. respiratory cluster

Tuesday, March 29, 2011 12:11 PM

CRO Celerion, which provides early-stage drug development solutions, said its Belfast facility has gained membership within the U.K. Respiratory Therapeutic Capability Cluster. Celerion will work with key decision makers in the U.K. to develop and execute phase I and IIa studies with targeted patient populations.

The U.K. Respiratory Therapeutic Capability Cluster is a cooperative of internationally leading clinicians and scientists whose aim is to improve the speed of developing innovative therapies for respiratory diseases by working in collaboration with research groups of the pharmaceutical industry. 

Celerion has access to laboratory capabilities (flow cytometry, flow cytometric cell sorting, microbiology, 16S, deep sequencing, MLST, transcriptomics) as well as lung imaging techniques (CT acquisition of images, dedicated MRI time, advanced CT analysis capabilities and MRI acquisition of images).  The collaboration with the U.K. Respiratory Therapeutic Capability Cluster provides access to patients suffering from asthma, COPD, cystic fibrosis, bronchiectasis and interstitial lung disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.